Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN AND METFORMIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN AND METFORMIN HCL.
KOMBIGLYZE XR vs SITAGLIPTIN AND METFORMIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), leading to glucose-dependent insulin secretion and decreased glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
Initial: 50 mg sitagliptin/500 mg metformin twice daily or 50 mg/1000 mg twice daily (max 100 mg/2000 mg per day). Dose adjusted gradually based on glycemic response and tolerability.
None Documented
None Documented
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Sitagliptin: terminal t1/2 12.4 hours; Metformin: terminal t1/2 6.2 hours (prolonged to 17.6 hours in renal impairment). Combination: effective t1/2 ~7-12 hours, dosing adjusted for CrCl <45 mL/min.
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Sitagliptin: 79% excreted unchanged in urine via active tubular secretion and glomerular filtration; 13% metabolized with minimal biliary/fecal elimination (1% unchanged in feces). Metformin: 90% excreted unchanged in urine via active tubular secretion; 0% biliary/fecal.
Category C
Category A/B
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor